studies

la/mBC - HR-positive - 1st line (L1), ribociclib plus letrozole vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsMONALEESA-2, 2016 0.76 [0.63; 0.92] 0.76[0.63; 0.92]MONALEESA-2, 201610%668NAnot evaluable progression or deaths (PFS)detailed resultsMONALEESA-2, 2016 0.56 [0.43; 0.72] 0.56[0.43; 0.72]MONALEESA-2, 201610%668NAnot evaluable CBRdetailed resultsMONALEESA-2, 2016 1.46 [1.02; 2.10] 1.46[1.02; 2.10]MONALEESA-2, 201610%668NAnot evaluable objective responses (ORR)detailed resultsMONALEESA-2, 2016 1.81 [1.31; 2.50] 1.81[1.31; 2.50]MONALEESA-2, 201610%668NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-10 08:41 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 1380

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons